Sporothrix species are commonly isolated from environmental and clinical samples. As common causes of zoonotic mycosis, Sporothrix species may result in localized or disseminated infections, posing considerable threat to animal and human health. However, the pathogenic profiles of different Sporothrix species varied, in virulence, geographic location and host ranges, which have yet to be explored. Analysing the genomes of Sporothrix species are useful for understanding their pathogenicity. In this study, we analyzed the whole genome of 12 Sporothrix species and six S. globosa isolates from different clinical samples in China. By combining comparative analyses with Kyoto Encyclopedia of Genes and Genomes (KEGG), Carbohydrate-Active enZymes (CAZy), antiSMASH, Pfam, and PHI annotations, Sporothrix species showed exuberant primary and secondary metabolism processes. The genome sizes of four main clinical species, i.e., S. brasiliensis, S. schenckii, S. globosa, and S. luriei were significantly smaller than other environmental and clinical Sporothrix species. The contracted genes included mostly CAZymes and peptidases genes that were usually associated with the decay of plants, as well as the genes that were associated with the loss of pathogenicity and the reduced virulence. Our results could, to some extent, explain a habitat shift of Sporothrix species from a saprobic life in plant materials to a pathogenic life in mammals and the increased pathogenicity during the evolution. Gene clusters of melanin and clavaric acid were identified in this study, which improved our understanding on their pathogenicity and possible antitumor effects. Moreover, our analyses revealed no significant genomic variations among different clinical isolates of S. globosa from different regions in China.

Vitiligo is a common and refractory disease worldwide. The limited efficiency and side effects of the conventional treatment options create demands towards the development of strategies. Excellent repigmentation is demonstrated after several filiform fire needle sessions in the vitiligo lesions. In this observational study, we aimed to observe the response to filiform fire needle therapy in patients with vitiligo, and determine whether there was a difference of efficiency with respect to the type, affected site, and disease duration of vitiligo. Patients received filiform fire needle therapy once every 2 weeks for 12 consecutive weeks. The results of the 77 vitiligo patients were: 34 (44.15%) with an excellent repigmentation rate, 15 (19.48%) with a marked improvement, 15 (19.48%) with a moderate response, 6 (7.79%) with a slight improvement, and 7 (9.09%) with an absent response. Among the vitiligo patients with different affected sites, the most effective location of therapy was the face. Shorter course leads to better therapeutic effect. Two patients developed hypertrophic scars on the lesion site. In conclusion, this study shows filiform fire needle therapy is an effective and relatively safe therapeutic option for vitiligo.